NCT05204121已完成1 期
Phase Ib, Single-Center, Randomized Study of Safety, Tolerability and Pharmacokinetics of Elpida in Healthy HIV-Uninfected Volunteers
Viriom1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2018年12月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Incidence of AEs and SAEs
研究概览
简要总结
A randomized once weekly dose for 8 weeks, study in Healthy HIV-Uninfected Volunteers. Each of 3 parallel groups (40 mg, 80 mg and 160mg) enrolls 12 subjects.
详细描述
The study aims to assess safety, tolerability and PK of once weekly administration of Elpida in different doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men and women aged 18 to 55 years;
- •Verified diagnosis "healthy" according to medical history, physical examination, assessment of vital signs, electrocardiography (ECG), investigations performed in the last 14 days prior to the first administration of IP;
- •Body mass index (BMI) from 18.5 kg/m2 to 30 kg/m2 (inclusive), bodyweight of 50 kg or higher;
- •Negative result of alcohol and drug tests;
- •Women must be in postmenopause for at least 2 years, be surgically sterile or use two reliable methods of contraception from the day of screening and until 3 months after the last dose;
- •Men must use two reliable methods of contraception* from the day of screening and until 3 months after the last dose;
- •Ability to understand the meaning of the study and any risks associated with participation. Ability to interact with the investigator, participate and comply with the requirements of the study throughout its duration;
- •Willingness to sign written consent to participate in the study after reading Informed Consent Form with the opportunity to discuss any questions with the investigator (and/or his/her representative).
排除标准
- •Participation in more than one group of investigational therapy;
- •Past or present diseases of the cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood that may interfere with achievement of objectives of this study or affect the safety of a volunteer;
- •The values of laboratory and instrumental parameters, beyond the limit of normal ;
- •Past or present diseases or pathologies, including surgical interventions in the gastrointestinal tract that, in the opinion of the Investigator, may affect the absorption, distribution, metabolism or excretion of the investigational product;
- •A systolic pressure of less than 90 mm Hg or greater than 130 mm Hg; diastolic pressure of less than 60 mm Hg or greater than 85 mm Hg; pulse rate of less than 60 bpm or greater than 90 bpm (at screening);
- •Deviations detected during 12-lead ECG, or QT/QTc interval > 450 milliseconds (ms) for men and > 470 ms for women;
- •Administration of any drugs n, including over-the-counter products, herbal, food, dietary or vitamin supplements 14 days before the first administration of the investigational product;
- •Administration of the following drugs for 28 days prior to screening: corticosteroids (any route of administration); IP that inhibit the activity of cytochrome P450 3A4 (CYP3A4; for example, ritonavir and other drugs for human immunodeficiency virus (HIV), ketoconazole, itraconazole, or similar azole antifungals and macrolide antibiotics such as erythromycin), or the use of any drugs with a significant likely effect on functions of organs (for example, barbiturates, omeprazole, cimetidine);
- •Hepatitis B (HBsAg), antibodies to hepatitis C and HIV, a positive test for syphilis;
- •Positive pregnancy test (for women);
- •Acute infectious diseases less than 4 weeks before screening;
- •Unstable sleeping hours (for example, night shift, sleep disorders, insomnia, jet lag, etc.);
- •Signs of alcohol or drug addiction; intake of alcohol or drugs 4 days prior to screening and during the study; smoking cigarettes 3 months prior to screening and during the study; positive drug and/or alcohol test;
- •Complicated allergic history (including intolerance to medication, including hypersensitivity to the active substance/excipients of the investigational drug) and food allergy;
- •Blood/plasma donation (450 mL of blood or plasma or more) less than 2 months before screening;
- •Participation in another clinical study or administration of any investigational products less than 3 months before screening;
- •Any other concomitant medical or significant mental conditions that render a volunteer unsuitable for participation in the clinical study;
- •A volunteer who is considered for enrollment in the study is an employee of the study site or company of the Sponsor or a member of an employee's family
研究组 & 干预措施
Elpida 40 mg once weekly
Experimental
elsulfavirine 40mg orally once weekly for 8 weeks
干预措施: Elpida (Drug)
Elpida 80 mg once weekly
Experimental
elsulfavirine 80mg orally once weekly for 8 weeks
干预措施: Elpida (Drug)
Elpida 160 mg once weekly
Experimental
elsulfavirine 160mg orally once weekly for 8 weeks
干预措施: Elpida (Drug)
结局指标
主要结局
Incidence of AEs and SAEs
时间窗: 77 days
Incidence of AEs and SAEs
次要结局
- VM1500A plasma concentration(77 days)
- elsulfavirine plasma concentration(77 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy VolunteersHIV InfectionsNCT03730311Viriom24
已完成
3 期
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)HIV-1 InfectionNCT04233216Merck Sharp & Dohme LLC35
已完成
2 期
Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing RegimenHuman Immunodeficiency VirusNCT00051844Pfizer179
已完成
3 期
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive SubjectsInfection, Human Immunodeficiency VirusNCT01449929ViiV Healthcare488
已完成
4 期
Safety and Effectiveness of a Combination Anti-HIV Drug TreatmentHIV InfectionsNCT00005018Glaxo Wellcome150